Health Economics›Pancreatic cancer›Metastatic disease first-line

Metastatic disease first-line

Pancreatic cancer · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Gemcitabine and nab-Paclitaxel Variant #01	—	R 65 179	28d	—	11.6 mo	2	R 130 357 PFS proxy	8
Erlotinib and Gemcitabine Variant #01	—	R 28 195	28d	—	6.1 mo	6	R 94 997 PFS proxy	2
Gemcitabine and Nimotuzumab Variant #01 Partial	—	R 10 033	56d	—	10.9 mo	2	R 20 065 PFS proxy	—
Capecitabine and Gemcitabine Variant #01	—	R 6 309	21d	—	7.9 mo	6	R 37 856 PFS proxy	4
GTX Variant #01	—	R 6 071	21d	—	—	~2	~R 12 142 indirect	—
PEFG Variant #01	—	R 4 977	28d	—	—	2	R 9 954 PFS proxy	1
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	—	7.4 mo	6	R 23 595 PFS proxy	1
FOLFIRINOX Variant #03	—	R 3 520	14d	—	11.4 mo	2	R 7 041 PFS proxy	2
GemOx Variant #01	—	R 2 937	14d	5.8 mo	9.0 mo	7	R 20 560 PFS proxy	2
NALIRIFOX Variant #01 Partial	—	R 2 803	14d	—	11.1 mo	2	R 5 606 PFS proxy	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	5.7 mo	6.6 mo	7	R 11 705 PFS proxy	21
Capecitabine monotherapy Variant #01	—	R 1 039	21d	—	—	~2	~R 2 077 PFS proxy · indirect	2
Fluorouracil monotherapy Variant #01	—	R 647	28d	—	4.4 mo	2	R 1 294 PFS proxy	—
S-1 monotherapy Variant #01 Partial	—	—	21d	—	9.7 mo	2	—	1

14 of 14 regimens shown